Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM)

Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM)

Background. The combination of chemotherapy plus anti HER-2 agents is the mainstay of HER-2 positive advanced breast cancer (ABC) therapy. We conducted a phase II trial testing activity and safety of trastuzumab and metronomic capecitabine/cyclophosphamide (HEX) as first-line therapy in HER-2 positi...

Full description

Bibliographic Details
Main Authors: Laura Orlando, Vito Lorusso, Francesco Giotta, Massimo Di Maio, Paola Schiavone, Palma Fedele, Annamaria Quaranta, Chiara Caliolo, Mariangela Ciccarese, Margherita Cinefra, Sante Romito, Salvatore Pisconti, Salvatore del Prete, Michele Aieta, Daniele Rizzi, Evaristo Maiello, Giuseppe Colucci, Saverio Cinieri
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:Breast
Subjects:
HER-2 positive
Metronomic chemotherapy
Advanced breast cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977620301223

Internet

http://www.sciencedirect.com/science/article/pii/S0960977620301223

Similar Items